Literature DB >> 8035486

Incorporation of homologous and heterologous proteins into the envelope of Moloney murine leukemia virus.

M Suomalainen1, H Garoff.   

Abstract

The efficiencies with which homologous and heterologous proteins are incorporated into the envelope of Moloney murine leukemia virus (M-MuLV) have been analyzed by utilizing a heterologous, Semliki Forest virus-driven M-MuLV assembly system and quantitative pulse-chase assays. Homologous M-MuLV spike protein was found to be efficiently incorporated into extracellular virus particles when expressed at a relatively low density at the plasma membrane. In contrast, efficient incorporation of heterologous proteins (the spike complex of Semliki Forest virus and a cytoplasmically truncated mutant of the human transferrin receptor) was observed only when these proteins were expressed at high densities at the cell surface. These results imply that homologous and heterologous proteins are incorporated into the M-MuLV envelope via two distinct pathways.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8035486      PMCID: PMC236428     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  59 in total

1.  In vitro mutagenesis of a full-length cDNA clone of Semliki Forest virus: the small 6,000-molecular-weight membrane protein modulates virus release.

Authors:  P Liljeström; S Lusa; D Huylebroeck; H Garoff
Journal:  J Virol       Date:  1991-08       Impact factor: 5.103

2.  Analysis of mutations in the envelope gene of Moloney murine leukemia virus: separation of infectivity from superinfection resistance.

Authors:  C Granowitz; J Colicelli; S P Goff
Journal:  Virology       Date:  1991-08       Impact factor: 3.616

3.  Cellular maturation of oncornavirus glycoproteins: topological arrangement of precursor and product forms in cellular membranes.

Authors:  O N Witte; A Tsukamoto-Adey; I L Weissman
Journal:  Virology       Date:  1977-02       Impact factor: 3.616

4.  Internally located cleavable signal sequences direct the formation of Semliki Forest virus membrane proteins from a polyprotein precursor.

Authors:  P Liljeström; H Garoff
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

5.  Pseudotype formation of murine leukemia virus with the G protein of vesicular stomatitis virus.

Authors:  N Emi; T Friedmann; J K Yee
Journal:  J Virol       Date:  1991-03       Impact factor: 5.103

6.  Role of the matrix protein in the virion association of the human immunodeficiency virus type 1 envelope glycoprotein.

Authors:  T Dorfman; F Mammano; W A Haseltine; H G Göttlinger
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

7.  A new generation of animal cell expression vectors based on the Semliki Forest virus replicon.

Authors:  P Liljeström; H Garoff
Journal:  Biotechnology (N Y)       Date:  1991-12

8.  Structure of Sindbis virus core protein reveals a chymotrypsin-like serine proteinase and the organization of the virion.

Authors:  H K Choi; L Tong; W Minor; P Dumas; U Boege; M G Rossmann; G Wengler
Journal:  Nature       Date:  1991-11-07       Impact factor: 49.962

9.  High frequency of aberrant expression of Moloney murine leukemia virus in clonal infections.

Authors:  A Shields; W N Witte; E Rothenberg; D Baltimore
Journal:  Cell       Date:  1978-07       Impact factor: 41.582

10.  Membrane fusion process of Semliki Forest virus. II: Cleavage-dependent reorganization of the spike protein complex controls virus entry.

Authors:  A Salminen; J M Wahlberg; M Lobigs; P Liljeström; H Garoff
Journal:  J Cell Biol       Date:  1992-01       Impact factor: 10.539

View more
  34 in total

1.  Minimal exclusion of plasma membrane proteins during retroviral envelope formation.

Authors:  M Hammarstedt; K Wallengren; K W Pedersen; N Roos; H Garoff
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-20       Impact factor: 11.205

2.  A biosensor assay for studying ligand-membrane receptor interactions: binding of antibodies and HIV-1 Env to chemokine receptors.

Authors:  T L Hoffman; G Canziani; L Jia; J Rucker; R W Doms
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-10       Impact factor: 11.205

3.  Interactions between the transmembrane segments of the alphavirus E1 and E2 proteins play a role in virus budding and fusion.

Authors:  Mathilda Sjöberg; Henrik Garoff
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

4.  An envelope glycoprotein of the human endogenous retrovirus HERV-W is expressed in the human placenta and fuses cells expressing the type D mammalian retrovirus receptor.

Authors:  J L Blond; D Lavillette; V Cheynet; O Bouton; G Oriol; S Chapel-Fernandes; B Mandrand; F Mallet; F L Cosset
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

5.  The nucleocapsid-binding spike subunit E2 of Semliki Forest virus requires complex formation with the E1 subunit for activity.

Authors:  B U Barth; H Garoff
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

Review 6.  Viral vectors: from virology to transgene expression.

Authors:  D Bouard; D Alazard-Dany; F-L Cosset
Journal:  Br J Pharmacol       Date:  2009-05       Impact factor: 8.739

7.  Efficient infection mediated by viral receptors incorporated into retroviral particles.

Authors:  J W Balliet; P Bates
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

8.  Measles viruses with altered envelope protein cytoplasmic tails gain cell fusion competence.

Authors:  T Cathomen; H Y Naim; R Cattaneo
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

9.  Primary attachment of murine leukaemia virus vector mediated by particle-associated heparan sulfate proteoglycan.

Authors:  Nina Kureishy; Daisy Faruque; Colin D Porter
Journal:  Biochem J       Date:  2006-12-15       Impact factor: 3.857

10.  Isomerization of the intersubunit disulphide-bond in Env controls retrovirus fusion.

Authors:  Michael Wallin; Maria Ekström; Henrik Garoff
Journal:  EMBO J       Date:  2003-12-11       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.